Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19611438 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2NPSR1SLC6A3SLC6A2KDM1A | |
| SCHEMBL19630869 | 0.80 | PDE4B (0.39) | MEN1KMT2A | |
| SCHEMBL19630849 | 0.79 | CYP3A4 (0.38) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14720455 | 0.78 | PSEN1 (0.48) | SMN1; SMN2 | |
| SCHEMBL19630901 | 0.77 | CYP2D6 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20216451 | 0.77 | CYP2D6 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16504401 | 0.76 | TSHR (0.41) | MEN1KMT2A | |
| SCHEMBL8314920 | 0.75 | TSHR (0.43) | — | |
| SCHEMBL20216325 | 0.75 | TSHR (0.47) | — | |
| SCHEMBL19627150 | 0.73 | MAOB (0.38) | SMN1; SMN2NPSR1SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-17 | — | — | US | disclosed |
| US-12195478-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4487913-A2 | OPIOID RECEPTOR MODULATORS | The Trustees Of Columbia University In The City Of New York (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-3224261-B1 | OPIOID RECEPTOR MODULATORS | UNIV COLUMBIA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-20170334923-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195478-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | MEN1 4819/4885KMT2A 1891/4885SMN1; SMN2 3917/4885 |
| US-20170334923-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MEN1 4864/4885KMT2A 1649/4885SMN1; SMN2 4640/4885 |
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MEN1 4819/4885KMT2A 1891/4885SMN1; SMN2 3917/4885 |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MEN1 4819/4885KMT2A 1891/4885SMN1; SMN2 3917/4885 |
| US-11840541-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | MEN1 4864/4885KMT2A 1649/4885SMN1; SMN2 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.